Metabolic Pathways Library
Every article, presentation, spotlight, and news item we've tagged to Metabolic Pathways.
Showing 145–148 of 148
GLP-1 Drugs’ Muscle Effects Similar to Ordinary Weight Loss
GLP-1 receptor agonists produce weight loss with lean body mass reduction comparable to caloric restriction alone, with minimal impact on muscle function. The reduction in lean body mass appears driven largely by liver mass loss rather than skeletal muscle depletion.
PNPLA3-Targeted RNA Therapy Cuts Liver Fat 46% in MASH
Madrigal acquired exclusive global rights to ARO-PNPLA3, an RNA interference therapy targeting PNPLA3 mutations that drive metabolic dysfunction-associated steatohepatitis. Phase 1 data demonstrated 46% reduction in liver fat within 12 weeks in genetically defined patients, establishing a precision-medicine approach to a disease affecting millions with limited treatment options.
Dual-pathway obesity therapy amplifies weight loss and metabolic resilience
OrsoBio's mitochondrial protonophore TLC-6740 produced an additional 4.5% weight loss when combined with tirzepatide, alongside improvements in insulin sensitivity and liver health, while demonstrating safety comparable to GLP-1 monotherapy. The approach targets energy expenditure rather than appetite suppression, representing a shift toward dual-pathway obesity treatment and metabolic resilience optimization.
Dual receptor agonist enters Phase 3 for fatty liver reversal
Altimmune has initiated Phase 3 testing of pemvidutide, a dual glucagon/GLP-1 receptor agonist, for metabolic dysfunction-associated steatohepatitis (MDASH). The compound represents a mechanistic approach to nonalcoholic fatty liver disease by simultaneously engaging two metabolic pathways implicated in hepatic fat accumulation and energy dysregulation.